Please login to the form below

Not currently logged in
Email:
Password:

Plethora

This page shows the latest Plethora news and features for those working in and with pharma, biotech and healthcare.

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

The company seems to be in safe hands with Disley at the helm; his career history is one that encompasses a plethora of scientific and financial dealings.

Latest news

  • Neurodegenerative disorders market set to reach $45bn by 2022 Neurodegenerative disorders market set to reach $45bn by 2022

    The majority of this growth is expected to take place from 2018, when a plethora of late-stage products are due to be submitted for regulatory approval.

  • Overriding the main frame Overriding the main frame

    It is better to have a plethora of great ideas to whittle down and prioritise later vs.

  • Explosive evolution Explosive evolution

    Most patients and payers, whatever their clinical and economic needs, will have many good and varied options to choose from, so most companies will have to compete against this plethora of

  • Money-back guarantee Money-back guarantee

    Despite the best designed RCTs, the plethora of real world experience, the input of peers and the development of evidence-based guidelines, the truth is that sometimes we simply don't

  • US seeking price cuts for Medicare drugs US seeking price cuts for Medicare drugs

    provision. A plethora of new drugs for cancer and other diseases are reaching the market that cost well upwards of $100, 000 a year, while the $1, 000-a-day price

More from news
Approximately 1 fully matching, plus 63 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • WHITE PAPER: Patient nonadherence – the $637bn paradox WHITE PAPER: Patient nonadherence – the $637bn paradox

    Latterly though, what has most certainly changed is the awareness of, and eagerness to address, issues of nonadherence through a plethora of incentives and initiatives; albeit, as yet, seemingly to little

  • Digitalising healthcare: what can the NHS learn from other industries?

    If you asked a patient, a physician, a pharmaceutical rep, or the average person on the street what digital health means to them, they would come back with a plethora of

  • Don’t just hope: COPE Don’t just hope: COPE

    COPEing with a plethora of user-preferences . It’s not just screen sizes and functionality that differ across devices.

  • Mixing up Focus Groups

    Life with diabetes requires a person to engage with a plethora of healthcare professionals; GPs, Endocrinologists, Diabetes Nurses, Nutritionists and Podiatrists to name but a few.

  • Artificial Intelligence in healthcare

    Despite a plethora of inspiring healthcare applications, in the NHS it is generally incumbent upon individual trusts to research and implement innovations into the fabric of healthcare provision and, while the

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics